英国 COVID-19 住院后的糖尿病发病率:前瞻性观察研究。

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2024-11-20 DOI:10.1111/dom.16071
Freya Tyrer PhD, Safoora Gharibzadeh PhD, Clare Gillies PhD, Claire Lawson PhD, Ash Routen PhD, Nazrul Islam MBBS, Cameron Razieh PhD, Francesco Zaccardi PhD, Tom Yates PhD, Melanie J. Davies MD, Christopher E. Brightling PhD, James D. Chalmers PhD, Annemarie B. Docherty PhD, Omer Elneima MRCP, Rachael A. Evans PhD, Neil J. Greening PhD, Victoria C. Harris MSc, Ewen M. Harrison PhD, Ling-Pei Ho PhD, Alex Horsley PhD, Linzy Houchen-Wolloff PhD, Olivia C. Leavy PhD, Nazir I. Lone PhD, Michael Marks PhD, Hamish J. C. McAuley MBBS, Krisnah Poinasamy MA, Jennifer K. Quint MBBS, Betty Raman DPhil, Matthew Richardson PhD, Ruth Saunders PhD, Marco Sereno MSc, Aarti Shikotra PhD, Amish Singapuri BSc, Louise V. Wain PhD, Kamlesh Khunti MedSci, the PHOSP-COVID Study Collaborative Group
{"title":"英国 COVID-19 住院后的糖尿病发病率:前瞻性观察研究。","authors":"Freya Tyrer PhD,&nbsp;Safoora Gharibzadeh PhD,&nbsp;Clare Gillies PhD,&nbsp;Claire Lawson PhD,&nbsp;Ash Routen PhD,&nbsp;Nazrul Islam MBBS,&nbsp;Cameron Razieh PhD,&nbsp;Francesco Zaccardi PhD,&nbsp;Tom Yates PhD,&nbsp;Melanie J. Davies MD,&nbsp;Christopher E. Brightling PhD,&nbsp;James D. Chalmers PhD,&nbsp;Annemarie B. Docherty PhD,&nbsp;Omer Elneima MRCP,&nbsp;Rachael A. Evans PhD,&nbsp;Neil J. Greening PhD,&nbsp;Victoria C. Harris MSc,&nbsp;Ewen M. Harrison PhD,&nbsp;Ling-Pei Ho PhD,&nbsp;Alex Horsley PhD,&nbsp;Linzy Houchen-Wolloff PhD,&nbsp;Olivia C. Leavy PhD,&nbsp;Nazir I. Lone PhD,&nbsp;Michael Marks PhD,&nbsp;Hamish J. C. McAuley MBBS,&nbsp;Krisnah Poinasamy MA,&nbsp;Jennifer K. Quint MBBS,&nbsp;Betty Raman DPhil,&nbsp;Matthew Richardson PhD,&nbsp;Ruth Saunders PhD,&nbsp;Marco Sereno MSc,&nbsp;Aarti Shikotra PhD,&nbsp;Amish Singapuri BSc,&nbsp;Louise V. Wain PhD,&nbsp;Kamlesh Khunti MedSci,&nbsp;the PHOSP-COVID Study Collaborative Group","doi":"10.1111/dom.16071","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>People hospitalised for coronavirus disease 2019 (COVID-19) have elevated incidence of diabetes. However, it is unclear whether this is due to shared risk factors, confounding or stress hyperglycaemia in response to acute illness.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We analysed a multicentre prospective cohort study (PHOSP-COVID) of people ≥18 years discharged from NHS hospitals across the United Kingdom following COVID-19. Individuals were included if they attended at least one research visit with a HbA1c measurement within 14 months of discharge and had no history of diabetes at baseline. The primary outcome was new onset diabetes (any type), as defined by a first glycated haemoglobin (HbA1c) measurement ≥6.5% (≥48 mmol/mol). Follow-up was censored at the last HbA1c measurement. Age-standardised incidence rates and incidence rate ratios (adjusted for age, sex, ethnicity, length of hospital stay, body mass index, smoking, physical activity, deprivation, hypertension, hyperlipidaemia/hypercholesterolaemia, intensive therapy unit admission, invasive mechanical ventilation, corticosteroid use and C-reactive protein score) were calculated using Poisson regression. Incidence rates were compared with the control groups of published clinical trials in the United Kingdom by applying the same inclusion and exclusion criteria, where possible.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Incidence of diabetes was 91.4 per 1000 person-years and was higher in South Asian (incidence rate ratios [IRR] = 3.60; 1.77, 7.32; <i>p</i> &lt; 0.001) and Black ethnic groups (IRR = 2.36; 1.07, 5.21; <i>p</i> = 0.03) compared with White ethnic groups. When restricted to similar characteristics, the incidence rates were similar to those in UK clinical trials data.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Diabetes incidence following hospitalisation for COVID-19 is high, but it remains uncertain whether it is disproportionately higher than pre-pandemic levels.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"27 2","pages":"767-776"},"PeriodicalIF":5.4000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16071","citationCount":"0","resultStr":"{\"title\":\"Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study\",\"authors\":\"Freya Tyrer PhD,&nbsp;Safoora Gharibzadeh PhD,&nbsp;Clare Gillies PhD,&nbsp;Claire Lawson PhD,&nbsp;Ash Routen PhD,&nbsp;Nazrul Islam MBBS,&nbsp;Cameron Razieh PhD,&nbsp;Francesco Zaccardi PhD,&nbsp;Tom Yates PhD,&nbsp;Melanie J. Davies MD,&nbsp;Christopher E. Brightling PhD,&nbsp;James D. Chalmers PhD,&nbsp;Annemarie B. Docherty PhD,&nbsp;Omer Elneima MRCP,&nbsp;Rachael A. Evans PhD,&nbsp;Neil J. Greening PhD,&nbsp;Victoria C. Harris MSc,&nbsp;Ewen M. Harrison PhD,&nbsp;Ling-Pei Ho PhD,&nbsp;Alex Horsley PhD,&nbsp;Linzy Houchen-Wolloff PhD,&nbsp;Olivia C. Leavy PhD,&nbsp;Nazir I. Lone PhD,&nbsp;Michael Marks PhD,&nbsp;Hamish J. C. McAuley MBBS,&nbsp;Krisnah Poinasamy MA,&nbsp;Jennifer K. Quint MBBS,&nbsp;Betty Raman DPhil,&nbsp;Matthew Richardson PhD,&nbsp;Ruth Saunders PhD,&nbsp;Marco Sereno MSc,&nbsp;Aarti Shikotra PhD,&nbsp;Amish Singapuri BSc,&nbsp;Louise V. Wain PhD,&nbsp;Kamlesh Khunti MedSci,&nbsp;the PHOSP-COVID Study Collaborative Group\",\"doi\":\"10.1111/dom.16071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>People hospitalised for coronavirus disease 2019 (COVID-19) have elevated incidence of diabetes. However, it is unclear whether this is due to shared risk factors, confounding or stress hyperglycaemia in response to acute illness.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We analysed a multicentre prospective cohort study (PHOSP-COVID) of people ≥18 years discharged from NHS hospitals across the United Kingdom following COVID-19. Individuals were included if they attended at least one research visit with a HbA1c measurement within 14 months of discharge and had no history of diabetes at baseline. The primary outcome was new onset diabetes (any type), as defined by a first glycated haemoglobin (HbA1c) measurement ≥6.5% (≥48 mmol/mol). Follow-up was censored at the last HbA1c measurement. Age-standardised incidence rates and incidence rate ratios (adjusted for age, sex, ethnicity, length of hospital stay, body mass index, smoking, physical activity, deprivation, hypertension, hyperlipidaemia/hypercholesterolaemia, intensive therapy unit admission, invasive mechanical ventilation, corticosteroid use and C-reactive protein score) were calculated using Poisson regression. Incidence rates were compared with the control groups of published clinical trials in the United Kingdom by applying the same inclusion and exclusion criteria, where possible.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Incidence of diabetes was 91.4 per 1000 person-years and was higher in South Asian (incidence rate ratios [IRR] = 3.60; 1.77, 7.32; <i>p</i> &lt; 0.001) and Black ethnic groups (IRR = 2.36; 1.07, 5.21; <i>p</i> = 0.03) compared with White ethnic groups. When restricted to similar characteristics, the incidence rates were similar to those in UK clinical trials data.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Diabetes incidence following hospitalisation for COVID-19 is high, but it remains uncertain whether it is disproportionately higher than pre-pandemic levels.</p>\\n </section>\\n </div>\",\"PeriodicalId\":158,\"journal\":{\"name\":\"Diabetes, Obesity & Metabolism\",\"volume\":\"27 2\",\"pages\":\"767-776\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2024-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.16071\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes, Obesity & Metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/dom.16071\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.16071","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:因冠状病毒病 2019(COVID-19)住院治疗的患者糖尿病发病率较高。然而,目前尚不清楚这是否是由于共同的风险因素、混杂因素或急性病应激性高血糖所致:我们分析了一项多中心前瞻性队列研究(PHOSP-COVID),研究对象是在 COVID-19 之后从英国国家医疗服务系统医院出院的年龄≥18 岁的患者。如果患者在出院后 14 个月内至少参加过一次 HbA1c 测量的研究访问,且基线时没有糖尿病史,则被纳入研究范围。主要结果是新发糖尿病(任何类型),即首次糖化血红蛋白 (HbA1c) 测量值≥6.5%(≥48 mmol/mol)。随访在最后一次测量 HbA1c 时终止。采用泊松回归法计算年龄标准化发病率和发病率比(根据年龄、性别、种族、住院时间、体重指数、吸烟、体力活动、贫困程度、高血压、高脂血症/高胆固醇血症、入住重症治疗室、有创机械通气、使用皮质类固醇和 C 反应蛋白评分进行调整)。在可能的情况下,采用相同的纳入和排除标准,将发病率与英国已发表临床试验的对照组进行比较:结果:糖尿病发病率为每千人年 91.4 例,南亚人的发病率更高(发病率比 [IRR] = 3.60; 1.77, 7.32; p 结论:糖尿病在南亚人中的发病率较高:因 COVID-19 而住院的糖尿病发病率很高,但仍不确定是否比大流行前的水平高出很多。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study

Background

People hospitalised for coronavirus disease 2019 (COVID-19) have elevated incidence of diabetes. However, it is unclear whether this is due to shared risk factors, confounding or stress hyperglycaemia in response to acute illness.

Methods

We analysed a multicentre prospective cohort study (PHOSP-COVID) of people ≥18 years discharged from NHS hospitals across the United Kingdom following COVID-19. Individuals were included if they attended at least one research visit with a HbA1c measurement within 14 months of discharge and had no history of diabetes at baseline. The primary outcome was new onset diabetes (any type), as defined by a first glycated haemoglobin (HbA1c) measurement ≥6.5% (≥48 mmol/mol). Follow-up was censored at the last HbA1c measurement. Age-standardised incidence rates and incidence rate ratios (adjusted for age, sex, ethnicity, length of hospital stay, body mass index, smoking, physical activity, deprivation, hypertension, hyperlipidaemia/hypercholesterolaemia, intensive therapy unit admission, invasive mechanical ventilation, corticosteroid use and C-reactive protein score) were calculated using Poisson regression. Incidence rates were compared with the control groups of published clinical trials in the United Kingdom by applying the same inclusion and exclusion criteria, where possible.

Results

Incidence of diabetes was 91.4 per 1000 person-years and was higher in South Asian (incidence rate ratios [IRR] = 3.60; 1.77, 7.32; p < 0.001) and Black ethnic groups (IRR = 2.36; 1.07, 5.21; p = 0.03) compared with White ethnic groups. When restricted to similar characteristics, the incidence rates were similar to those in UK clinical trials data.

Conclusion

Diabetes incidence following hospitalisation for COVID-19 is high, but it remains uncertain whether it is disproportionately higher than pre-pandemic levels.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
期刊最新文献
Multiomics analysis of O-GlcNAcylation in podocytes of diabetic kidney disease. Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Validation of the 2024 European Association for the Study of Obesity diagnostic criteria: A comprehensive assessment of obesity-related mortality risks. Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. Association between remnant cholesterol and chronic kidney disease: Systematic review and meta-analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1